Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma

M Ladetto; S Ferrero; D Drandi; M Festuccia; F Patriarca; N Mordini; S Cena; R Benedetto; G Guarona; F Ferrando; L Brunello; P Ghione; V Boccasavia; R Fanin; P Omedè; L Giaccone; A Palumbo; R Passera; M Boccadoro; B Bruno

doi:10.1038/leu.2015.269

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma

Leukemia. 2016 May;30(5):1211-4. doi: 10.1038/leu.2015.269. Epub 2015 Oct 6.

Authors

M Ladetto^{1

2

3}, S Ferrero^{1

2}, D Drandi^{1

2}, M Festuccia^{1

2}, F Patriarca⁴, N Mordini⁵, S Cena¹, R Benedetto^{1

2}, G Guarona^{1

2}, F Ferrando¹, L Brunello^{1

2}, P Ghione^{1

2}, V Boccasavia¹, R Fanin⁴, P Omedè¹, L Giaccone^{1

2}, A Palumbo^{1

2}, R Passera⁶, M Boccadoro^{1

2}, B Bruno^{1

2}

Affiliations

¹ Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
² Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
³ Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
⁴ Division of Hematology, A.O.U, Udine, DISM, University of Udine, Udine, Italy.
⁵ Division of Hematology, Ospedale 'S.Croce e Carle', Cuneo, Italy.
⁶ Division of Nuclear Medicine, Statistical Consultant, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.

PMID: 26437784
DOI: 10.1038/leu.2015.269

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Hematopoietic Stem Cell Transplantation*
Humans
Multiple Myeloma / genetics*
Multiple Myeloma / therapy*
Neoplasm, Residual*
Prospective Studies
Real-Time Polymerase Chain Reaction
Recurrence
Transplantation Conditioning / methods*
Transplantation, Homologous